Major Depressive Disorder News and Research

RSS

Major Depressive Disorder (MDD) is a psychiatric condition characterized by depressed mood or anhedonia (significant loss of interest or pleasure). The condition affects more than 15.7 million adults and approximately 3 million adolescents (aged 13 to 17 years) in the USA each year.

Physical activity may help lower genetic risk of depression in adults

Adding physical activity to a daily routine may seem like a simple step for better health, but research from Kansas State University suggests it could be especially beneficial for individuals with a genetic predisposition to depression, potentially helping reduce their risk and ease their symptom burden.

26 Oct 2026

Depression profile linked to disrupted sleep and poorer treatment responses

This study uncovers a circadian depression subtype, revealing links between sleep patterns, symptom severity, and antidepressant response in a large cohort.

22 Oct 2026

New study explores psychedelic therapy for co-occurring cocaine addiction and depression

A team of UTHealth Houston researchers has been awarded a five-year, $3.4 million grant to study whether psilocybin-assisted therapy is a viable treatment option for individuals with co-occurring cocaine use disorder and major depressive disorder.

22 Oct 2026

Accelerated TMS cuts depression treatment time from six weeks to three

Transcranial magnetic stimulation (TMS) has proved to be a very effective non-invasive treatment for people with severe depression who have not had success with medication. But traditional TMS has one significant drawback: time.

21 Oct 2026

Global study aims to map brain changes across eight psychiatric disorders

Researchers from the Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI) at the Keck School of Medicine of USC will lead a worldwide effort to map how eight common psychiatric disorders affect brain function, supported by a five-year, $3.2 million grant from the National Institutes of Health.

21 Oct 2026

Hyponatremia risk varies among individual second-generation antipsychotic drugs

Antipsychotics are used to treat schizophrenia, along with bipolar disorder and major depressive disorder. However, these medications can be associated with hyponatremia, a serious reduction in blood sodium levels.

8 Oct 2026

Study reveals lasting brain changes linked to childhood maltreatment

Childhood abuse leaves a scar on the brain, a new neuroimaging study led by UCLA psychologists has shown.

6 Oct 2026

USC researchers receive $4 million to test psychedelic therapy and mindfulness for depression

A team of USC researchers has received an up to $4 million award from the Advanced Research Projects Agency for Health (ARPA-H) to conduct a clinical trial of psychedelic therapy and mindfulness training for depression.

6 Oct 2026

NIH-funded trials will test pregnenolone for addiction and depression

Center for BrainHealth investigator Francesca Filbey, PhD, and UTSW investigator Sherwood Brown, MD, PhD, have secured two awards from the National Institutes of Health (NIH) to fund two major collaborative studies investigating whether the naturally occurring neurosteroid pregnenolone can help treat substance use disorders and co-occurring depression.

1 Oct 2026

New framework maps depression symptoms to unique brain circuits

A research team from the Sant Pau Research Institute (IR Sant Pau) has published a scientific review proposing a paradigm shift in the way depression is understood and studied.

1 Oct 2026

The heart effects of antidepressants may depend as much on the patient as the drug

Antidepressants differed in their effects on QTc, with amitriptyline and escitalopram producing small average increases, and the magnitude of changes varying according to individual patient characteristics. The trials did not detect an increase in early major cardiovascular events or non-suicidal sudden death, but they were not large or long enough to rule out rare or later cardiovascular events.

24 Sep 2026

Brain activity study reveals five distinct profiles for depression

As two people with considerably different symptoms may receive the same depression diagnosis, researchers wanted to determine whether this individuality also manifests in brain activity.

23 Sep 2026

Add-on drug lumateperone boosts sexual function in patients with depression

Patients with major depressive disorder (MDD) and an inadequate response to standard antidepressants who received an add- on treatment with the drug lumateperone saw significantly improved sexual function, found a new study led by a University of Virginia School of Medicine researcher.

15 Sep 2026

Astrocyte changes may explain how stress affects mental health

A new study led by UCLA Health researchers has identified a specific type of brain cell and a tiny structure on its surface that changes when the body is under stress, which may help explain why stress can lead to anxiety and depression.

8 Sep 2026

GLP-1 drugs appear psychiatrically safe, but one finding still raises questions

A systematic review of 11 observational studies representing more than 4.9 million patients found that GLP-1 receptor agonists were generally associated with neutral or potentially protective psychiatric outcomes, although one obesity-focused cohort reported increased risks of depression, anxiety, and suicidal behavior. Direct evidence for antidepressant effects remains limited, with only one cross-sectional study using validated mood scales and no randomized trials in the final synthesis, meaning causality cannot be established

6 Sep 2026

Does a psychedelic need an awake brain to have lasting effects? This mouse study offers a clue

A single dose of psilocybin produced a lasting increase in sociability for at least two weeks in Cntnap2-knockout mice with social deficits, while it did not enhance sociability overall in mice with normal social behavior. The effect required 5-HT2A receptor activation and persisted when psilocybin was administered under light anesthesia, suggesting that wakefulness during the drug’s acute effects was not necessary for this behavioral response.

30 Aug 2026

Probiotics for mental health? A new review finds promising signals and major gaps

This narrative review examines how psychobiotics may influence anxiety, depression, bipolar disorder, and schizophrenia through gut-brain pathways involving neurotransmitters, inflammation, immune regulation, gut barrier function, and stress signaling. Specific Lactobacillus and Bifidobacterium strains showed encouraging effects, but wide differences in strains, doses, populations, and study designs currently limit clinical translation.

28 Aug 2026

Neurogenesis stalls in the brains of adults with major depressive disorder, study shows

Most of our brain's 100 billion neurons are created before we're born, but the trickle of neurons created in the adult brain hippocampus could be instrumental in preventing depression, suggest findings from a new study by researchers at Columbia University Vagelos College of Physicians and Surgeons.

21 Aug 2026

Single-dose psilocybin shows promise for treatment-resistant depression in NHS trial

A single 25-mg dose of psilocybin with psychological support was feasible to deliver within an NHS setting and produced large preliminary reductions in depressive symptoms among adults with treatment-resistant depression. The Phase 2 feasibility trial also found the treatment was generally well tolerated, although functional unblinding and expectancy effects mean larger, longer efficacy studies are needed.

10 Aug 2026

Inflammatory bowel disease linked to elevated risk of psychiatric disorders

Patients with inflammatory bowel disease (IBD) face a significantly higher risk of psychiatric disorders starting two to three years before diagnosis and lasting up to a decade after, according to a nationwide study to be published in Clinical Gastroenterology and Hepatology.

5 Aug 2026